1119 related articles for article (PubMed ID: 19213682)
1. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.
Hütter G; Nowak D; Mossner M; Ganepola S; Müssig A; Allers K; Schneider T; Hofmann J; Kücherer C; Blau O; Blau IW; Hofmann WK; Thiel E
N Engl J Med; 2009 Feb; 360(7):692-8. PubMed ID: 19213682
[TBL] [Abstract][Full Text] [Related]
2. CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report.
Duarte RF; Salgado M; Sánchez-Ortega I; Arnan M; Canals C; Domingo-Domenech E; Fernández-de-Sevilla A; González-Barca E; Morón-López S; Nogues N; Patiño B; Puertas MC; Clotet B; Petz LD; Querol S; Martinez-Picado J
Lancet HIV; 2015 Jun; 2(6):e236-42. PubMed ID: 26423196
[TBL] [Abstract][Full Text] [Related]
3. Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.
Wang C; Abdel-Mohsen M; Strain MC; Lada SM; Yukl S; Cockerham LR; Pilcher CD; Hecht FM; Sinclair E; Liegler T; Richman DD; Deeks SG; Pillai SK
J Infect Dis; 2014 Dec; 210(11):1838-43. PubMed ID: 24935955
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.
Gupta RK; Abdul-Jawad S; McCoy LE; Mok HP; Peppa D; Salgado M; Martinez-Picado J; Nijhuis M; Wensing AMJ; Lee H; Grant P; Nastouli E; Lambert J; Pace M; Salasc F; Monit C; Innes AJ; Muir L; Waters L; Frater J; Lever AML; Edwards SG; Gabriel IH; Olavarria E
Nature; 2019 Apr; 568(7751):244-248. PubMed ID: 30836379
[TBL] [Abstract][Full Text] [Related]
5. CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.
Henrich TJ; Hanhauser E; Harrison LJ; Palmer CD; Romero-Tejeda M; Jost S; Bosch RJ; Kuritzkes DR
J Infect Dis; 2016 Mar; 213(5):766-70. PubMed ID: 26512140
[TBL] [Abstract][Full Text] [Related]
6. Relationship between CCR5
Martínez-Bonet M; González-Serna A; Clemente MI; Morón-López S; Díaz L; Navarro M; Puertas MC; Leal M; Ruiz-Mateos E; Martinez-Picado J; Muñoz-Fernández MA
Clin Microbiol Infect; 2017 May; 23(5):318-324. PubMed ID: 28042001
[TBL] [Abstract][Full Text] [Related]
7. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
8. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation.
Allers K; Hütter G; Hofmann J; Loddenkemper C; Rieger K; Thiel E; Schneider T
Blood; 2011 Mar; 117(10):2791-9. PubMed ID: 21148083
[TBL] [Abstract][Full Text] [Related]
9. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.
Tebas P; Jadlowsky JK; Shaw PA; Tian L; Esparza E; Brennan AL; Kim S; Naing SY; Richardson MW; Vogel AN; Maldini CR; Kong H; Liu X; Lacey SF; Bauer AM; Mampe F; Richman LP; Lee G; Ando D; Levine BL; Porter DL; Zhao Y; Siegel DL; Bar KJ; June CH; Riley JL
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33571163
[TBL] [Abstract][Full Text] [Related]
10. Cord blood transplantation for cure of HIV infections.
Petz L
Stem Cells Transl Med; 2013 Sep; 2(9):635-7. PubMed ID: 23884642
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion.
Sheppard HW; Celum C; Michael NL; O'Brien S; Dean M; Carrington M; Dondero D; Buchbinder SP
J Acquir Immune Defic Syndr; 2002 Mar; 29(3):307-13. PubMed ID: 11873082
[TBL] [Abstract][Full Text] [Related]
12. Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?
Laurichesse JJ; Taieb A; Capoulade-Metay C; Katlama C; Villes V; Drobacheff-Thiebaud MC; Raffi F; Chêne G; Theodorou I; Leport C;
HIV Med; 2010 Apr; 11(4):239-44. PubMed ID: 20050936
[TBL] [Abstract][Full Text] [Related]
13. Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32.
Henrich TJ; Hanhauser E; Hu Z; Stellbrink HJ; Noah C; Martin JN; Deeks SG; Kuritzkes DR; Pereyra F
AIDS; 2015 May; 29(8):867-76. PubMed ID: 25730507
[TBL] [Abstract][Full Text] [Related]
14. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C.
Woitas RP; Ahlenstiel G; Iwan A; Rockstroh JK; Brackmann HH; Kupfer B; Matz B; Offergeld R; Sauerbruch T; Spengler U
Gastroenterology; 2002 Jun; 122(7):1721-8. PubMed ID: 12055576
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia.
Xu L; Wang J; Liu Y; Xie L; Su B; Mou D; Wang L; Liu T; Wang X; Zhang B; Zhao L; Hu L; Ning H; Zhang Y; Deng K; Liu L; Lu X; Zhang T; Xu J; Li C; Wu H; Deng H; Chen H
N Engl J Med; 2019 Sep; 381(13):1240-1247. PubMed ID: 31509667
[TBL] [Abstract][Full Text] [Related]
16. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients.
Wit FW; van Rij RP; Weverling GJ; Lange JM; Schuitemaker H
J Infect Dis; 2002 Dec; 186(12):1726-32. PubMed ID: 12447757
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 Infection in Persons Homozygous for CCR5-Δ32 Allele: The Next Case and the Review.
Smoleń-Dzirba J; Rosińska M; Janiec J; Beniowski M; Cycoń M; Bratosiewicz-Wąsik J; Wąsik TJ
AIDS Rev; 2017 Dec; 19(4):219-230. PubMed ID: 28534889
[TBL] [Abstract][Full Text] [Related]
18. Protection against parenteral HIV-1 infection by homozygous deletion in the C-C chemokine receptor 5 gene.
Kupfer B; Kaiser R; Brackmann HH; Effenberger W; Rockstroh JK; Matz B; Schneweis KE
AIDS; 1999 Jun; 13(9):1025-8. PubMed ID: 10397531
[TBL] [Abstract][Full Text] [Related]
19. HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group.
Katzenstein TL; Eugen-Olsen J; Hofmann B; Benfield T; Pedersen C; Iversen AK; Sørensen AM; Garred P; Koppelhus U; Svejgaard A; Gerstoft J
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Sep; 16(1):10-4. PubMed ID: 9377119
[TBL] [Abstract][Full Text] [Related]
20. Rapid Rebound of a Preexisting CXCR4-tropic Human Immunodeficiency Virus Variant After Allogeneic Transplantation With CCR5 Δ32 Homozygous Stem Cells.
Verheyen J; Thielen A; Lübke N; Dirks M; Widera M; Dittmer U; Kordelas L; Däumer M; de Jong DCM; Wensing AMJ; Kaiser R; Nijhuis M; Esser S
Clin Infect Dis; 2019 Feb; 68(4):684-687. PubMed ID: 30020413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
